Komori

FY2025 results briefing materials

Results presentationPublished 2025-11-14 16:00

2025年9月期は、売上高が増え、営業損失もほぼ解消しました。補助金の計上や外注費の削減により、創業以来初めて経常黒字となり、2026年9月期も経常黒字を見込んでいます。

Contents of this document

Financial results presentationFiscal year ended September 20254 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,075 million
Operating profit¥-4 million
Ordinary income¥156 million
Net income¥127 million
Selling, general and administrative expenses¥646 million
Full-year earnings forecast
Net Sales
¥1,046 million
Operating profit
¥-148 million
Ordinary income
¥13 million
Net income for the current fiscal year
¥9 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales102.7%
Ordinary income1,140.1%
Net income for the current fiscal year1,313.8%
Revenue breakdown
国策案件・研究開発受託(Stage2)
Earnings Forecast¥403 million
Actual results¥410 million
民間案件・研究開発受託(Stage2)
Earnings Forecast¥522 million
Actual results¥493 million
民間案件・ライセンス・自社販売・テクノロジーパッケージ(Stage3)
Earnings Forecast¥120 million
Actual results¥172 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
売上高は計画どおり、営業利益・経常利益・当期純利益は予想を大きく上回った
New initiatives
  • 木質バイオマスからバイオエタノールを生産する年産1,000kLのセミコマーシャルプラントの建設
  • 森空バイオリファイナリー合同会社の設立
  • 日本航空、エアバス等と連携した国産SAF向けバイオエタノールの事業化
  • 東証スタンダード市場への市場区分変更申請に向けた準備
Key KPIsA metric the company considers important as a management benchmark.
  • 売上高+営業外収入(バイオものづくり事業に関連する収益のみ)More than ¥1 billion
    Year on year against the same period last yearFor the second consecutive year
  • 2025年9月期に売上を計上したパイプライン22 Projects
  • バイオファウンドリ事業の生産性3x
Capital expenditures
¥310 millions research and development expenses
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredFiscal year ended September 2025
Net Sales¥1,075 million
Operating profit¥-4 million
Ordinary income¥156 million
Net income¥127 million
Selling, general and administrative expenses¥646 million
Full-year earnings forecastNet Sales ¥1,046 million / Operating profit ¥-148 million / Ordinary income ¥13 million / Net income for the current fiscal year ¥9 million
Progress against full-year forecastNet Sales 102.7% / Operating profit Not disclosed / Ordinary income 1,140.1% / Net income for the current fiscal year 1,313.8% / Revenue breakdown 国策案件・研究開発受託(Stage2) Earnings Forecast ¥403 million / Actual results ¥410 million / 民間案件・研究開発受託(Stage2) Earnings Forecast ¥522 million / Actual results ¥493 million / 民間案件・ライセンス・自社販売・テクノロジーパッケージ(Stage3) Earnings Forecast ¥120 million / Actual results ¥172 million
Self-assessment against the plan売上高は計画どおり、営業利益・経常利益・当期純利益は予想を大きく上回った
Key KPIsIndicator name 売上高+営業外収入(バイオものづくり事業に関連する収益のみ) / Value More than ¥1 billion / Year on year against the same period last year For the second consecutive year, Indicator name 2025年9月期に売上を計上したパイプライン / Value 22 Projects / Year on year against the same period last year Not disclosed, Indicator name バイオファウンドリ事業の生産性 / Value 3x / Year on year against the same period last year Not disclosed
Capital expenditures¥310 millions (research and development expenses)
New initiatives木質バイオマスからバイオエタノールを生産する年産1,000kLのセミコマーシャルプラントの建設, 森空バイオリファイナリー合同会社の設立, 日本航空、エアバス等と連携した国産SAF向けバイオエタノールの事業化, 東証スタンダード市場への市場区分変更申請に向けた準備
Items this document does not state (18)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

FY2025 results briefing materials | Green Earth Institute Co.,Ltd. (9212) timely disclosure | Komori